Author(s): Coch C, Luck C, Schwickart A, Putschli B, Renn M, et al.
Therapeutic oligonucleotides including siRNA and immunostimulatory ligands of Toll-like receptors (TLR) or RIG-I like helicases (RLH) are a promising novel class of drugs. They are in clinical development for a broad spectrum of applications, e.g. as adjuvants in vaccines and for the immunotherapy of cancer. Species-specific immune activation leading to cytokine release is characteristic for therapeutic oligonucleotides either as an unwanted side effect or intended pharmacology. Reliable in vitro tests designed for therapeutic oligonucleotides are therefore urgently needed in order to predict clinical efficacy and to prevent unexpected harmful effects in clinical development. To serve this purpose, we here established a human whole blood assay (WBA) that is fast and easy to perform. Its response to synthetic TLR ligands (R848: TLR7/8, LPS: TLR4) was on a comparable threshold to the more time consuming peripheral blood mononuclear cell (PBMC) based assay. By contrast, the type I IFN profile provoked by intravenous CpG-DNA (TLR9 ligand) in humans in vivo was more precisely replicated in the WBA than in stimulated PBMC. Since Heparin and EDTA, but not Hirudin, displaced oligonucleotides from their delivery agent, only Hirudin qualified as the anticoagulant to be used in the WBA. The Hirudin WBA exhibited a similar capacity as the PBMC assay to distinguish between TLR7-activating and modified non-stimulatory siRNA sequences. RNA-based immunoactivating TLR7/8- and RIG-I-ligands induced substantial amounts of IFN-α in the Hirudin-WBA dependent on delivery agent used. In conclusion, we present a human Hirudin WBA to determine therapeutic oligonucleotide-induced cytokine release during preclinical development that can readily be performed and offers a close reflection of human cytokine response in vivo.
Referred From: https://doi.org/10.1371/journal.pone.0071057
Author(s): Chin KL, Anis FZ, Sarmiento ME, Norazmi MN, Acosta A, et al.
Author(s): Negishi H, Taniguchi T, Yanai H
Author(s): Di Franco S, Turdo A, Todaro M, Stassi G
Author(s): Bessis N, GarciaCozar FJ, Boissier MC
Author(s): Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H, et al.
Author(s): Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, et al.
Author(s): Lennox KA, Behlke MA
Author(s): Leeds JM, Henry SP, Geary R, Burckin T, Levin AA, et al.
Author(s): Behlke MA
Author(s): Jacobi AM, Rettig GR, Turk R, Collingwood MA, Zeiner SA, et al.
Author(s): Neun BW, Dobrovolskaia MA
Author(s): Neun BW, Dobrovolskaia MA
Author(s): Potter TM, Neun BW, Rodriguez JC, Ilinskaya AN, Dobrovolskaia MA, et al.
Author(s): Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, et al.
Author(s): Daneshian M, Von Aulock S, Hartung T
Author(s): Dobrovolskaia MA
Author(s): Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, et al.
Author(s): Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, et al.
Author(s): Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, et al.
Author(s): Alvarez-Salas LM
Author(s): Henry SP, Geary RS, Yu R, Levin AA
Author(s): Holmlund JT, Monia BP, Kwoh TJ, Dorr FA
Author(s): Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al.
Author(s): Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA
Author(s): Keefe AD, Pai S, Ellington A
Author(s): Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al.